Media Coverage

2017

April 25, 2017
Medpage Today: NASH Drugs Take Center Stage

Apr 24, 2017
FierceBiotech: Merck-backed NGM Bio hits its marks in midstage NASH trial

April 24, 2017
Endpoints: EASL Roundup: Bristol-Myers and NGM post a positive look at PhII NASH data; Genfit details PhIII delay

April 22, 2017
BioPharma Dive: EASL: Experimental drug slashes fatty liver markers in Phase 2

2016

September 20, 2016
Bloomberg: Big Pharma, Biotech Attack NASH Liver Illness From All Sides

May 23, 2016
SF Business Times: Another Genentech? These are the most likely companies

May 4, 2016
PharmaLive: NGM Plans Move to Vacant Site Once Meant for Amgen

May 3, 2016
SF Business Times: Emerging biotech company preps fall takeover of never-used Amgen space

2015

October 1, 2015
FierceBiotech: The 2015 Fierce 15 biotech execs take a bow

March 9, 2015
Nasdaq: Merck’s Partnership With NGM Is A Bold Move

March 3, 2015
BioSpace: Backed By a Genentech Alum, NGM Looks Like it Could be the Next Biotech IPO
BioPharma: Merck & Co and NGM Biopharmaceutical team to take on obesity and diabetes

February 24, 2015
WSJ: ‘We Had a Bird in the Hand, but…’ NGM Chose Merck: Rieflin Explains

February 23, 2015
Bloomberg: Merck’s Research Man Saved Biotech Deal With One Last Fat Pitch
WSJ: Merck to Team With NGM to Develop Diabetes Treatment
FierceBiotech: Merck bets big on NGM with a $450M handshake
Forbes.com: Merck Bets $450M On ‘Old School’ Biotech From NGM
Xconomy: Well-Funded NGM Bio Nabs $200M To Boost Merck’s Metabolic Pipeline

2013

July 19, 2013
San Francisco Business Times: As biotech VC fundings rise, NGM snags $50 million

July 18, 2013
BioWorld: NGM’s Series C Garners $50M for Ongoing Work in Diabetes
FierceBiotech: NGM completes $50M Series C to advance cardio-metabolic therapies

June 25, 2013
Xconomy: NGM, Partners Seek Next Diabetes Drug Targets Among GI Tract Hormones

June 18, 2013
The Pink Sheet: MedImmune And NGM To Collaborate On Drugs To Mimic Benefits Of Bariatric Surgery (behind paywall)

June 17, 2013
PharmaTimes: AstraZeneca signs obesity and diabetes pact with NGM

May 3, 2013
SF Business Times: Diabetes drug developer NGM Biopharma, led by Genentech vets Levinson and Goeddel, raises $13.5 million

2010

May 15, 2010
SF Business Times: NGM closes 1st tranche of $51M round